Since GM-CSF and granulocyte colony stimulating factor (G-CSF) were approved by FDA in the 1990s, they were both widely used to treat various types of cancer patients with chemotherapy-induced neutropenia and leucopenia, and achieved an excellent result. This evidence concerns the gene CSF2 and neutropenia.